NEWAMSTERDAM PHARMA COMPANY's ticker is and the CUSIP is N62509109.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,300,000 | $110,058 | 13.76% |
| Medicxi Ventures Management (Jersey) Ltd | 2,000,000 | $26,520,000 | 11.36% |
| Frazier Life Sciences Management, L.P. | 9,341,551 | $125,550,445 | 9.09% |
| RA Capital Management | 4,000,000 | $53,040,000 | 1.20% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,535,723 | $33,623,687 | 0.75% |
| BVF INC/IL | 1,521,948 | $20,454,981 | 0.75% |
| GMT CAPITAL CORP | 1,083,800 | $14,371,188 | 0.56% |
| Parkman Healthcare Partners LLC | 115,000 | $1,524,900 | 0.33% |
| VIKING GLOBAL INVESTORS LP | 3,915,870 | $52,629,293 | 0.25% |
| Eversept Partners, LP | 45,856 | $608,051 | 0.04% |